Biden Falls Short on Pledge for U.S. to Be the World’s Vaccine ‘Arsenal,’ Experts Say

Con­gress appro­pri­at­ed $16 bil­lion to ramp up Covid-19 coun­ter­mea­sures, but a new report found that the Biden admin­is­tra­tion had spent very lit­tle of it on expand­ing vac­cine man­u­fac­tur­ing capacity.



Tags: design TT Mod­ell­bahn TT H0 N schal­ten mod­elleisen­bahn bahn spiele­max preise 

Ein Reichsmarschall von Adolf Hitler hatte auch Märklin Modelleisenbahn Modelle > read more

What to Know About Boosters if You Got the Johnson & Johnson Vaccine

Health experts say that boost­ers are like­ly to be need­ed even­tu­al­ly and that more data should be avail­able in the next sev­er­al weeks. Tags: design TT Mod­ell­bahn TT H0 N schal­ten mod­elleisen­bahn bahn spiele­max preise  Ein […]



Tags: design TT Mod­ell­bahn TT H0 N schal­ten mod­elleisen­bahn bahn spiele­max preise 

Ein Reichsmarschall von Adolf Hitler hatte auch Märklin Modelleisenbahn Modelle > read more

F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Covid Vaccine

Fed­er­al reg­u­la­tors con­clud­ed that the risk of devel­op­ing the syn­drome was low, and that the ben­e­fits of the vac­cine still strong­ly out­weigh it.

Emergent BioSolutions Faces Investor Revolt Over Botched Vaccines

In the lat­est share­hold­er law­suit, a pen­sion fund accused exec­u­tives at Emer­gent BioSo­lu­tions of insid­er trad­ing. The com­pa­ny, under inves­ti­ga­tion by Con­gress, has halt­ed man­u­fac­tur­ing of Covid-19 vac­cines at its Bal­ti­more fac­to­ry at reg­u­la­tors’ request.

Biotech Company That Botched Vaccines Faces Investor Revolt

In the lat­est share­hold­er law­suit, a pen­sion fund accused exec­u­tives at Emer­gent BioSo­lu­tions of insid­er trad­ing. The com­pa­ny, under inves­ti­ga­tion by Con­gress, has halt­ed man­u­fac­tur­ing of Covid-19 vac­cines at its Bal­ti­more fac­to­ry at reg­u­la­tors’ request.

Three Studies, One Result: Vaccines Point the Way Out of the Pandemic

New sci­en­tif­ic research under­scores the effec­tive­ness of vac­cines and their ver­sa­til­i­ty in the fight against the coronavirus.

High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S.

Pro­duc­tion prob­lems and a brief pause on its use kept the one-dose vac­cine from becom­ing the game chang­er that health offi­cials across the coun­try believed it would be.

Vaccine Maker Earned Record Profits but Delivered Disappointment in Return

Emer­gent BioSo­lu­tions was award­ed a $628 mil­lion fed­er­al con­tract with no com­pet­i­tive bid­ding. Top exec­u­tives received big bonus­es while fac­to­ries most­ly sat idle and tens of mil­lions of Covid-19 dos­es were thrown away.